Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation.

MLA

Kang, Yei-Jin, et al. “Administration of 4‑hexylresorcinol Increases P53‑mediated Transcriptional Activity in Oral Cancer Cells with the P53 Mutation.” Oncology Reports, vol. 48, no. 3, Sept. 2022. EBSCOhost, https://doi.org/10.3892/or.2022.8375.

APA

Kang, Y.-J., Yang, W.-G., Chae, W.-S., Kim, D.-W., Kim, S.-G., & Rotaru, H. (2022). Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation. Oncology Reports, 48(3). https://doi.org/10.3892/or.2022.8375

Chicago

Kang, Yei-Jin, Won-Geun Yang, Weon-Sik Chae, Dae-Won Kim, Seong-Gon Kim, and Horatiu Rotaru. 2022. “Administration of 4‑hexylresorcinol Increases P53‑mediated Transcriptional Activity in Oral Cancer Cells with the P53 Mutation.” Oncology Reports 48 (3). doi:10.3892/or.2022.8375.